(Q28214984)

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

The EVI1 gene in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021

An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205095

7 January 2021